PPD unveils new additions in a number of therapeutic areas

Doctors talking
PPD announced several new hires, expanding its therapeutics areas in neuroscience, hematology/oncology, rare diseases and pediatrics. (Getty/wmiami)

CRO Pharmaceutical Product Development (PPD) unveiled a number of new hires as part of the company’s goal to expand several therapeutics areas, including neuroscience, hematology/oncology, rare diseases and pediatrics.

The additions include Amy Chappell, M.D., and Alberto Lledó, M.D., Ph.D. Both Chappell and Lledó work in the area of neuroscience. Timothy Miller, M.D., was added in rare diseases and pediatrics, and Konstantin Stoitchkoy, M.D., Ph.D. in hematology/oncology. All have extensive experience in product development and commercialization, the company said.

“As the drug development process continues to become more complex, our clients are looking to PPD to provide medical and scientific expertise and strategic direction that extend far beyond traditional clinical trial implementation,” Rob Dow, PPD’s chief medical officer, said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Earlier this year, PPD and its patient-recruitment business unit, Acurian, launched a “patient concierge” service as part of an effort to increase trial enrollment and retention. The program proactively guides participants for the duration of a clinical study and manages their logistics, including appointment and medication reminders, device training, transportation and reimbursement support.


Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.